moneyhouse.ch moneyhouse.ch Robert Ober - beruflicher Werdegang, Wohn- und Heimatort View Robert Obers professional profile on LinkedIn. Kennt möglicherweise: Mario Bonorand, Werner Weber. We look forward to a successful collaboration. moneyhouse.ch Personal-Fürsorge-Stiftung Robert Ober AG, Zürich Aktuell tätig für: Robert Ober AG, Personal-Fürsorge-Stiftung Robert Ober AG, weitere. EUROPROTEOME is an ideal partner to achieve this objective."Ĭhristian Knobloch, M.D., Vice President Business Development, EUROPROTEOME, added: "We are very pleased that the value of EEUROPROTEOME's capabilities to merge both molecular and clinical data is being recognized by a top tier pharmaceutical company. ![]() This will allow for the stratification of patients who will benefit most from targeted cancer therapeutics. Find out more about EUROPROTEOME AG including the VentureRadar Innovation and Growth scores, Similar Companies and more. Europroteome AG Revenue: 5.40 Million Employees: 1 Industry: Biotechnology, Pharmaceuticals, Healthcare View Europroteome AGs full company profile > Rocketreach finds email, phone & social media for 450M+ professionals. "Molecular profiling of tissue specimens from cancer patients will be an important step in the development of novel cancer drugs. Europroteome AG Revenue: 5.40 Million Employees: 1 Industry: Biotechnology, Pharmaceuticals, Healthcare View Europroteome AG's full company profile > Rocketreach finds email, phone & social media for 450M+ professionals. Karl Sanders, Head Therapeutic Area Oncology at ALTANA Pharma AG. "We believe this collaboration will greatly enhance our knowledge about the clinical relevance of novel cancer targets," said Dr. The molecular data will then be aligned with a selected set of clinical data such as cancer stage and disease progression in order to assess disease associated expression signatures and prioritize molecular target candidates for therapeutic intervention with novel drugs and accompanying diagnostics for disease control. Similar companies and competitors including the VentureRadar Innovation and Growth scores, Company Information, Location and more. It filed its patents most often in EPO (European Patent Office), Australia and WIPO (World Intellectual Property Organization). Its first patent ever was published in 1998. The Rosetta Resolver system, which is being distributed by Agilent Technologies, is designed to be used with a variety of third-party and internally-developed DNA microarray technologies. EUROPROTEOME AG has a total of 35 patent applications. The company was founded in 1998 and is based in Hennigsdorf, Germany. Under the agreement, EUROPROTEOME will use its proprietary collection of purified human cancer cells to analyze molecular expression of a panel of cancer targets. Europroteome AG licenses Rosetta Resolver Gene Expression Data Analysis system. Europroteome AG develops diagnostic, immunological, and prognostic tools as well as patient-specific therapies for human epithelial cancers. EUROPROTEOME AG announced that it has entered into a collaboration for evaluation of approaches for molecular profiling of tissue specimens from cancer patients with ALTANA Pharma AG. Awema AG, bisher in Pfäffikon, CHE-106.961.499, Aktiengesellschaft (SHAB Nr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |